PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.

Research in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY is a prestigious academic journal dedicated to advancing the field of pharmaceutical biotechnology by publishing high-quality research articles, reviews, and innovatory methodologies. Published by Bentham Science Publishers Ltd, this journal has established a strong reputation in its field, reflected in its 2023 Scopus rankings: it holds an impressive Q2 classification in Pharmaceutical Science and Q3 in Biotechnology, indicating its significant impact within these disciplines. With an ISSN of 1389-2010 and an E-ISSN of 1873-4316, CURRENT PHARMACEUTICAL BIOTECHNOLOGY provides a reliable platform for disseminating valuable research findings and fostering collaboration among researchers, professionals, and students alike. The journal covers a wide array of topics, from drug development and delivery systems to innovative biotechnological techniques, thus serving as an essential resource for anyone interested in the cross-section of pharmaceutical science and biotechnology. Researchers can access a diverse range of articles that explore both theoretical frameworks and practical applications, reflecting the ongoing evolution and challenges in this dynamic field.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

Natural Products Journal, a leading publication by Bentham Science Publishers, primarily focuses on the rapidly evolving field of Natural Products and their applications in Complementary and Alternative Medicine as well as Drug Discovery. With an ISSN of 2210-3155 and an E-ISSN of 2210-3163, this journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the critical role of natural compounds in health and medicine. Since its inception in 2011, it has consolidated its reputation, achieving a Q3 ranking in Complementary and Alternative Medicine and a Q4 ranking in Drug Discovery as of 2023, illustrating its growing influence within the academic community. Although it currently does not operate as an Open Access journal, it remains a vital resource for cutting-edge research and developments in natural products, offering insightful contributions that pave the way for innovative therapeutic strategies. Located in the Netherlands, the journal is pivotal for those looking to stay at the forefront of research in natural substances and their multifaceted applications.